Hemcheck has received positive feedback from the trial at the Liverpool Heart and Chest Hospital, which was designed to assess the potential clinical use of Hemcheck’s products related to cardiac surgeries performed at the hospital. The next steps will be to do a second phase validation, which will commence if and once approved by a local ethical committee.
– The positive feedback is good news and we are very glad that Liverpool Heart and Chest Hospital has a continued interest in evaluating our products in this new area, after the first phase. This can lead to revenues and open new opportunities for us, if this evaluation is proven to be successful, says Joen Averstad, CEO of Hemcheck.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.